What is the purpose of the 2018 Employee Share Purchase Plan (ESPP)?

The 2018 ESPP allows eligible employees to purchase BeiGene, Ltd. ordinary shares (or ADSs) at the end of each offering period (typically six months) at a 15% discount to the market price. This is intended to incentivize employees and align their interests with shareholders by providing an opportunity to invest in the company's stock.

Why did BeiGene adopt the 2018 Inducement Equity Plan, and what does it entail?

The 2018 Inducement Equity Plan was adopted to provide equity awards to individuals who are not previously employees of the company. This plan, which reserves 12,000,000 ordinary shares, is designed as a material inducement to attract new talent to the company, in compliance with NASDAQ listing rules that allow for such grants without shareholder approval.

How has the compensation for independent directors changed?

The amended Independent Director Compensation Policy now includes an annual cash retainer of $50,000, plus additional fees for committee service ranging from $5,000 to $22,500 annually. Furthermore, independent directors will receive equity awards valued at $300,000 upon their initial election or appointment, and annually thereafter. These equity awards consist of half stock options and half restricted share units (RSUs).

What were the outcomes of the shareholder votes at the Annual General Meeting?

Shareholders re-elected three Class II directors, approved the 2018 ESPP, ratified the appointment of Ernst & Young Hua Ming LLP as the auditor, and approved executive compensation on an advisory basis. They also voted in favor of holding future advisory votes on executive compensation annually.

ONC/BEIGF 8-K: Leadership Changes & Shareholder Matters

Summary

This 8-K filing from BeOne Medicines Ltd. (operating as BeiGene, Ltd.) details key corporate governance and compensation decisions made at their 2018 Annual General Meeting of Shareholders held on June 6, 2018. The most significant investor-focused information revolves around the adoption of new equity incentive plans and amendments to director compensation. Specifically, shareholders approved the 2018 Employee Share Purchase Plan (ESPP), which allows eligible employees to purchase company shares at a discount. Additionally, the company adopted the 2018 Inducement Equity Plan, reserving shares for new hires as a recruitment incentive, and amended its Independent Director Compensation Policy, increasing both cash retainers and equity awards for non-employee directors. The filing also reports on the successful re-election of three Class II directors (Donald W. Glazer, Michael Goller, and Thomas Malley) and the ratification of Ernst & Young Hua Ming LLP as the independent auditor. Furthermore, shareholders provided a non-binding advisory vote of approval for executive compensation and indicated a preference for annual advisory votes on compensation going forward. These actions reflect the company's ongoing efforts to incentivize employees, attract talent, and align director compensation with market practices.

Key Highlights

1Shareholders approved the BeiGene, Ltd. 2018 Employee Share Purchase Plan (2018 ESPP), allowing eligible employees to purchase company shares at a 15% discount.
2The company adopted the 2018 Inducement Equity Plan, reserving 12,000,000 ordinary shares for grants to new employees as a recruitment incentive, without requiring shareholder approval.
3The Independent Director Compensation Policy was amended to increase annual cash retainers and equity awards for independent directors, with equity awards valued at $300,000 upon initial election and annually thereafter.
4Three Class II directors, Donald W. Glazer, Michael Goller, and Thomas Malley, were re-elected to their positions.
5The appointment of Ernst & Young Hua Ming LLP as the company's independent registered public accounting firm for the year ending December 31, 2018, was ratified.
6Shareholders provided a non-binding advisory vote approving the compensation of the Company's named executive officers.
7An advisory vote determined that future shareholder votes on executive compensation will be held on an annual basis.

BeOne Medicines Ltd. 8-K Report, Executive Changes (Jun 8, 2018)

Summary

Key Highlights

Frequently Asked Questions